Can Aqualase replace phaco?

Article

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification.

Removal of soft cataracts with Aqualase (Alcon), theoretically carries less risk to the posterior capsule than phacoemulsification, according to a report published in the February issue of Eye.

Laurence Whitefield and colleagues from Queen Mary's Hospital, Kent, UK, enrolled 33 subjects (mean age 71.4 years) to undergo cataract surgery using Aqualase through a 3.2 mm corneal incision. Grade of nucleus, nuclear removal technique and intraoperative complications were recorded.

The researchers found that Aqualase is capable of removing cataracts up to nuclear sclerosis 2+ fairly easily. Nuclei that were graded 2+ or greater were more technically difficult and conversion to ultrasound phacoemulsification was required in one case. Of the 33 procedures there were just two cases of posterior capsule rupture. One occurred during nucleus removal and the other was unrelated to Aqualase. A total of 96% of the subjects, without preoperative comorbidity, achieved 6/9 or better postoperatively.

The researchers feel that Aqualase does have an advantage over phacoemulsification, as it carries less risk of damage to the posterior capsule. Additionally, the method is similar enough to phacoemulsification to ensure that the learning curve is not too steep. However, they emphasize that Aqualase it is not completely risk free as rupture is possible with the floor pedal in position two.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.